Defendant

Roxane Laboratories, Inc.

13 cases as defendant.

Cases
13
Active
2
11 closed
Filed
2010–2020
Top venue
D N J
4 cases
Also appears as a plaintiff in 3 cases → View as plaintiff

Company profile

Roxane Laboratories, Inc. — also shortened to Roxane — was a U.S. generic and specialty pharmaceutical manufacturer headquartered at 1809 Wilson Road, Columbus, Ohio. Its predecessor, Columbus Pharmacal, dates to 1885; the business was renamed Philips Roxane after a 1959 acquisition by Philips and became Roxane Laboratories after Boehringer Ingelheim acquired it in 1978. Until 2016 it operated as a subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT). Press accounts and a Hikma acquisition prospectus describe a c. 875,000 sq-ft Columbus manufacturing/R&D site and roughly 1,000–1,360 employees. In February 2016 Hikma Pharmaceuticals PLC acquired Roxane for approximately $2.65 billion ($2.1 billion net, cash plus stock), folding it into its U.S. West-Ward business; the legal entity became Hikma Labs Inc. and the Columbus site became West-Ward Columbus.

Products / operations. Roxane was an operating company, not an NPE. It developed and sold generic (multisource) prescription drugs under ANDAs, plus some NDAs, spanning immediate-release and controlled-release oral solids, oral liquids and unit-dose liquids, nasal sprays, cytotoxics, dry-powder inhalers, high-potency compounds, and DEA Schedule II–V controlled substances (e.g., morphine sulfate, zaleplon). Its customers were wholesalers, retail chains, and group purchasing organizations, with essentially all revenue from the U.S. market.

Litigation posture. The tracked data show 13 cases as defendant and 3 as plaintiff — the profile of an operating generics manufacturer sued by brand-name patent holders over ANDA/Paragraph IV filings, most notably Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc. (D.N.J., from 2010 onward) concerning sodium oxybate (Xyrem). Roxane also appeared as a petitioner/plaintiff at the PTAB in 2014 (Roxane v. Jazz), typical of ANDA defendants challenging Orange Book patents. Its suits cluster in the District of New Jersey rather than plaintiff-friendly Texas venues.

Notable context. The 2020 New York State Teamsters Council Health & Hospital Fund v. Jazz Pharmaceuticals cases (N.D. Cal.) are follow-on antitrust/monopolization actions tied to Xyrem, in which Roxane's successor entities were named. Post-2016, ownership of several Roxane ANDAs (e.g., iloperidone) was transferred to West-Ward/Hikma subsidiaries.

Filing activity

2010: 2 cases'102011: 1 case'112012: 2 cases'12'13'142015: 2 cases'15'16'17'18'192020: 3 cases3'20
Cases filed per year naming Roxane Laboratories, Inc. as defendant.

Jazz Pharmaceuticals, Inc. et al. v. Roxane Laboratories, Inc.

settled
Docket:
2:15-cv-01360
Filed:
2015-02-20
Patents:8772306

The '306 patent was asserted; Roxane moved to dismiss the '306 claims on §101 subject-matter eligibility, which the court administratively terminated and stayed discovery on pending IPR. The case was consolidated with Roxane's '302 case on Mar 24, 2016 and settled in April 2017.

Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc. et al.

settled
Docket:
2:12-cv-06761
Court:
D.N.J.
Filed:
2012-10-26
Terminated:
2017-04-05
Patents:8263650

Jazz sued Roxane Laboratories (later Hikma/West-Ward) asserting the '650 patent. The case was consolidated with 2:10-cv-06108 and 2:12-cv-07459 in April 2013, and the consolidated case settled April 5, 2017, granting Hikma/West-Ward an authorized generic of Xyrem beginning Jan. 1, 2023.

Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.

consolidated; claims later invalidated via IPRs
Docket:
2:10-cv-06108
Court:
D.N.J.
Filed:
2010-11-22
Patents:7765107

Lead/first ANDA Hatch-Waxman case filed by Jazz Pharmaceuticals against Roxane Laboratories. The complaint expressly asserted US 7,765,107 along with other patents ('889, '219, '730, '106); the '107 claims were later invalidated via IPR2015-00547.

Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.

settled
Docket:
2:10-cv-06108
Court:
D.N.J.
Filed:
2010-11-22
Terminated:
2017-04-05
Patents:7262219

Lead Hatch-Waxman action asserting the '219 patent against Roxane; consolidated with several related Roxane actions. Claim construction issued 2012-09-14 and the case settled before trial.

Jazz Pharmaceuticals, Inc. et al. v. Roxane Laboratories, Inc. et al.

settled
Docket:
2:10-cv-06108

Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.